Design Therapeutics DSGN
NASDAQ DSGN
$12.24 -0.33 (-2.63%)
At close: Oct 1, 2026 · 4:00 PM EDT

Design Therapeutics (DSGN) Accumulated Expenses (2020 - 2021)

Updated

Design Therapeutics (DSGN) reported Accumulated Expenses of $1.82 million for Q2 2021, up 8.8% from the prior quarter.

Analysis

Design Therapeutics (DSGN) Accumulated Expenses (2020 - 2021) Analysis & Trends

At the end of FY2020, Design Therapeutics posted Accumulated Expenses of $931,000.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Design Therapeutics 786.63 Mn -69.40 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2021 1.82 Mn
Mar 31, 2021 1.67 Mn
Dec 31, 2020 931,000.00
API Access

Design Therapeutics Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=DSGN&period=max&api_key=YOUR_API_KEY